Physiomics Plc – Strategy, SWOT and Corporate Finance Report

Physiomics Plc – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.

Physiomics plc (Physiomics) is a computational systems biology services company. It offers Virtual Tumour, which optimizes the dosing and scheduling of oncology drugs in pre-clinical trials, cardiac toxicity services through its EasyAP, a Web-based simulation and analysis tool. It also offers model based drug development services, which includes population PKPD analysis of clinical data, back-translational analysis, optimal design of future studies. It is involved in developing outsourced systems and computational systems biology models for predicting and understanding cancer drug efficacy from pre-clinical research to clinical development and finding optimal schedules. The company provides consulting services for specific pharmaceutical development projects and provides trouble-shooting services for cancer projects. Physiomics partners with small and large pharmaceutical and biotechnology companies. Physiomics is headquartered at Oxford, England, the UK.

Scope

Detailed information on Physiomics Plc required for business and competitor intelligence needs

A study of the major internal and external factors affecting Physiomics Plc in the form of a SWOT analysis

An in-depth view of the business model of Physiomics Plc including a breakdown and examination of key business segments

News about Physiomics Plc, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Physiomics Plc and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Physiomics Plc as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Physiomics Plcs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Elekta AB

Cyprotex Ltd

Gunsynd Plc

Avacta Group Plc

e-Therapeutics Plc

Sareum Holdings Plc

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1 - About the Company 5

Physiomics Plc - Key Facts 5

Physiomics Plc - Key Employees 6

Physiomics Plc - Key Employee Biographies 7

Physiomics Plc - Major Products and Services 8

Physiomics Plc - History 9

Physiomics Plc - Company Statement 12

Physiomics Plc - Locations And Subsidiaries 13

Head Office 13

Section 2 Company Analysis 14

Company Overview 14

Physiomics Plc - Business Description 15

Physiomics Plc - Corporate Strategy 16

Physiomics Plc - SWOT Analysis 17

SWOT Analysis - Overview 17

Physiomics Plc - Strengths 17

Physiomics Plc - Weaknesses 18

Physiomics Plc - Opportunities 19

Physiomics Plc - Threats 20

Physiomics Plc - Key Competitors 21

Section 3 Company Financial Ratios 22

Financial Ratios - Capital Market Ratios 22

Financial Ratios - Annual Ratios 23

Performance Chart 25

Financial Performance 25

Financial Ratios - Interim Ratios 26

Financial Ratios - Ratio Charts 27

Section 4 Company’s Lifesciences Financial Deals and Alliances 28

Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Physiomics Plc, Recent Deals Summary 30

Section 5 Company’s Recent Developments 31

Oct 08, 2018: Physiomics: Final Results for the year ended 30 June 2018 31

Aug 09, 2018: Physiomics signs agreement with new european biotech client 33

Jul 02, 2018: Physiomics expands technical team 34

Apr 04, 2018: Physiomics to Present at the American Association for Cancer Research ("AACR") Annual Meeting 35

Mar 14, 2018: Physiomics: Award of New Innovate UK Grant 36

Mar 12, 2018: Physiomics: Completion of Innovate UK Grant Project on Personalised Treatment of Oesophageal Cancer 37

Feb 19, 2018: Physiomics: Interim Results Statement for the six-month period ended 31 December 2017 38

Feb 09, 2018: Physiomics secures third major pharmaceutical client in matter of months 40

Jan 26, 2018: Physiomics: New Major Pharmaceutical Client 41

Nov 28, 2017: Completion of VT Clinical Project with Merck and announcement of Master Services Agreement 42

Section 6 Appendix 43

Methodology 43

Ratio Definitions 43

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Tables

List of Tables

Physiomics Plc, Key Facts 5

Physiomics Plc, Key Employees 6

Physiomics Plc, Key Employee Biographies 7

Physiomics Plc, Major Products and Services 8

Physiomics Plc, History 9

Physiomics Plc, Key Competitors 21

Physiomics Plc, Ratios based on current share price 22

Physiomics Plc, Annual Ratios 23

Physiomics Plc, Annual Ratios (Cont…1) 24

Physiomics Plc, Interim Ratios 26

Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Physiomics Plc, Recent Deals Summary 30

Currency Codes 43

Capital Market Ratios 43

Equity Ratios 44

Profitability Ratios 44

Cost Ratios 45

Liquidity Ratios 45

Leverage Ratios 46

Efficiency Ratios 46

List of Figures

List of Figures

Physiomics Plc, Performance Chart (2014 – 2018) 25

Physiomics Plc, Ratio Charts 27

Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Physiomics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports